.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Predict branded drug patent expiration
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Mallinckrodt
Deloitte
Fuji
Baxter
Argus Health
Federal Trade Commission
Accenture
Cantor Fitzgerald
Boehringer Ingelheim
Cipla

Generated: July 24, 2017

DrugPatentWatch Database Preview

ZOLOFT Drug Profile

« Back to Dashboard

What is the patent landscape for Zoloft, and when can generic versions of Zoloft launch?

Zoloft is a drug marketed by Pfizer and is included in two NDAs. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has forty-nine patent family members in forty-five countries.

The generic ingredient in ZOLOFT is sertraline hydrochloride. There are twenty-two drug master file entries for this compound. Sixty-one suppliers are listed for this compound. Additional details are available on the sertraline hydrochloride profile page.

Summary for Tradename: ZOLOFT

Patents:2
Applicants:1
NDAs:2
Suppliers / Packagers: see list13
Bulk Api Vendors: see list47
Clinical Trials: see list123
Patent Applications: see list2,580
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:ZOLOFT at DailyMed

Pharmacology for Tradename: ZOLOFT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer
ZOLOFT
sertraline hydrochloride
TABLET;ORAL019839-005Mar 6, 1996ABRXYesNo► Subscribe► Subscribe► Subscribe
Pfizer
ZOLOFT
sertraline hydrochloride
CONCENTRATE;ORAL020990-001Dec 7, 1999AARXYesYes► Subscribe► SubscribeY► Subscribe
Pfizer
ZOLOFT
sertraline hydrochloride
TABLET;ORAL019839-003Dec 30, 1991DISCNYesNo► Subscribe► Subscribe► Subscribe
Pfizer
ZOLOFT
sertraline hydrochloride
TABLET;ORAL019839-001Dec 30, 1991ABRXYesNo► Subscribe► Subscribe► Subscribe
Pfizer
ZOLOFT
sertraline hydrochloride
TABLET;ORAL019839-002Dec 30, 1991ABRXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: ZOLOFT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer
ZOLOFT
sertraline hydrochloride
CONCENTRATE;ORAL020990-001Dec 7, 1999► Subscribe► Subscribe
Pfizer
ZOLOFT
sertraline hydrochloride
CONCENTRATE;ORAL020990-001Dec 7, 1999► Subscribe► Subscribe
Pfizer
ZOLOFT
sertraline hydrochloride
TABLET;ORAL019839-001Dec 30, 1991► Subscribe► Subscribe
Pfizer
ZOLOFT
sertraline hydrochloride
TABLET;ORAL019839-002Dec 30, 1991► Subscribe► Subscribe
Pfizer
ZOLOFT
sertraline hydrochloride
TABLET;ORAL019839-004Dec 30, 1991► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: ZOLOFT

Drugname Dosage Strength RLD Submissiondate
sertraline hydrochlorideTablets150 mg and 200 mgZoloft11/9/2005

International Patent Family for Tradename: ZOLOFT

Country Document Number Estimated Expiration
South Africa200102900► Subscribe
China1323202► Subscribe
Peru11082000► Subscribe
Slovakia4582001► Subscribe
Argentina014082► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Accenture
US Department of Justice
Queensland Health
Chubb
Colorcon
Cipla
McKesson
Cerilliant
Argus Health
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot